{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22","value":"14"},{"groupId":"OG001","spread":"26","value":"22"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"12"},{"groupId":"OG001","spread":"27","value":"22"}]}],"title":"3 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"13"},{"groupId":"OG001","spread":"31","value":"33"}]}],"title":"12 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21","value":"15"},{"groupId":"OG001","spread":"22","value":"17"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21","value":"15"},{"groupId":"OG001","spread":"23","value":"14"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17","value":"7"},{"groupId":"OG001","spread":"27","value":"15"}]}],"title":"18 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"Effects of therapy on work productivity and activity - Activity Impairment because of health, evaluated using the Work Productivity and Activity Impairment Questionnaire (WPAI-SHP), which defined per protocol.","dispersionType":"Standard Deviation","groups":[{"description":"T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks","id":"OG000","title":"Trastuzumab Emtansine (T-DM1)"},{"description":"paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments","id":"OG001","title":"Paclitaxel + Trastuzumab (TH)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Surveys are took at week 3, 12 and month 6 and 12 during treatment, and month 18, 24, 30 and 36 during follow up.","title":"Percentage of Activity Impairment Because of Health","type":"SECONDARY","unitOfMeasure":"percentage of time"}